JPWO2021255684A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021255684A5 JPWO2021255684A5 JP2022577503A JP2022577503A JPWO2021255684A5 JP WO2021255684 A5 JPWO2021255684 A5 JP WO2021255684A5 JP 2022577503 A JP2022577503 A JP 2022577503A JP 2022577503 A JP2022577503 A JP 2022577503A JP WO2021255684 A5 JPWO2021255684 A5 JP WO2021255684A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- flexneri
- glucose
- glycosylation
- consensus sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 41
- 230000002163 immunogen Effects 0.000 claims description 40
- 150000004676 glycans Polymers 0.000 claims description 32
- 229920001282 polysaccharide Polymers 0.000 claims description 26
- 239000005017 polysaccharide Substances 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 25
- 241000147000 Shigella flexneri 2a Species 0.000 claims description 20
- 241000607760 Shigella sonnei Species 0.000 claims description 20
- 108091035707 Consensus sequence Proteins 0.000 claims description 18
- 230000004988 N-glycosylation Effects 0.000 claims description 18
- 241001353153 Shigella flexneri 3a Species 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 16
- 241001353149 Shigella flexneri 6 Species 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 241000607768 Shigella Species 0.000 claims description 9
- 150000004804 polysaccharides Polymers 0.000 claims description 9
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 8
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- XOCCAGJZGBCJME-VAYLDTTESA-N N-Acetyl-L-Fucosamine Chemical compound C[C@@H]1OC(O)[C@@H](NC(C)=O)[C@H](O)[C@@H]1O XOCCAGJZGBCJME-VAYLDTTESA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 230000005875 antibody response Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 102000009016 Cholera Toxin Human genes 0.000 claims description 4
- 108010049048 Cholera Toxin Proteins 0.000 claims description 4
- 101000756556 Escherichia coli O157:H7 Multidrug efflux pump subunit AcrA Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 230000004989 O-glycosylation Effects 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- -1 sodium borate) Chemical compound 0.000 claims description 4
- 229940074404 sodium succinate Drugs 0.000 claims description 4
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 241000589875 Campylobacter jejuni Species 0.000 claims description 3
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical group OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940118376 tetanus toxin Drugs 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 9
- 108700023372 Glycosyltransferases Proteins 0.000 description 6
- 102000051366 Glycosyltransferases Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 4
- 241000205834 Escherichia coli O16 Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 101150057996 rfaL gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 101710102974 O-acetyl transferase Proteins 0.000 description 2
- 101710204495 O-antigen ligase Proteins 0.000 description 2
- 101100338058 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) gtrS gene Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 description 1
- 101100454725 Escherichia coli (strain K12) leuE gene Proteins 0.000 description 1
- 241000606999 Plesiomonas shigelloides Species 0.000 description 1
- 241000405383 Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012615 high-resolution technique Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 101150029321 wzzB gene Proteins 0.000 description 1
- 101150005995 yahL gene Proteins 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040844P | 2020-06-18 | 2020-06-18 | |
| US63/040,844 | 2020-06-18 | ||
| US202063043883P | 2020-06-25 | 2020-06-25 | |
| EP20182139 | 2020-06-25 | ||
| US63/043,883 | 2020-06-25 | ||
| EP20182139.4 | 2020-06-25 | ||
| EP20182138 | 2020-06-25 | ||
| EP20182138.6 | 2020-06-25 | ||
| PCT/IB2021/055361 WO2021255684A1 (en) | 2020-06-18 | 2021-06-17 | Shigella-tetravalent (shigella4v) bioconjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530154A JP2023530154A (ja) | 2023-07-13 |
| JPWO2021255684A5 true JPWO2021255684A5 (de) | 2024-06-20 |
Family
ID=76502778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577503A Pending JP2023530154A (ja) | 2020-06-18 | 2021-06-17 | 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346902A1 (de) |
| EP (1) | EP4168040A1 (de) |
| JP (1) | JP2023530154A (de) |
| CN (1) | CN115697396A (de) |
| BR (1) | BR112022024294A2 (de) |
| CA (1) | CA3185719A1 (de) |
| MX (1) | MX2022016587A (de) |
| WO (1) | WO2021255684A1 (de) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| ES2353814T3 (es) | 2005-05-11 | 2011-03-07 | Eth Zuerich | Proteinas n-glicosiladas recombinantes de celulas procariotas. |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2357184B1 (de) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazochinoxalinverbindungen als Immunmodulatoren |
| ES2652416T3 (es) | 2006-12-13 | 2018-02-02 | The Governors Of The University Of Alberta | Métodos y sistemas para la O-glicosilación de proteínas |
| CN101983070B (zh) | 2008-02-20 | 2016-03-30 | 格林考瓦因有限公司 | 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物 |
| DK2501406T3 (en) | 2009-11-19 | 2018-02-26 | Glaxosmithkline Biologicals Sa | BIOSYNTHESE SYSTEM PRODUCING IMMUNOGENIC POLYSACCHARIDES IN PROCARYOTIC CELLS |
| CA2887133C (en) * | 2012-10-12 | 2022-05-03 | Glycovaxyn Ag | Methods of host cell modification |
| CA2940547C (en) | 2014-02-24 | 2021-01-05 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2021
- 2021-06-17 WO PCT/IB2021/055361 patent/WO2021255684A1/en active Application Filing
- 2021-06-17 BR BR112022024294A patent/BR112022024294A2/pt unknown
- 2021-06-17 US US18/001,551 patent/US20230346902A1/en active Pending
- 2021-06-17 EP EP21733220.4A patent/EP4168040A1/de active Pending
- 2021-06-17 MX MX2022016587A patent/MX2022016587A/es unknown
- 2021-06-17 CN CN202180043251.6A patent/CN115697396A/zh active Pending
- 2021-06-17 JP JP2022577503A patent/JP2023530154A/ja active Pending
- 2021-06-17 CA CA3185719A patent/CA3185719A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI751513B (zh) | E. coli O-抗原多醣生物結合物、其製備方法及其使用方法 | |
| TWI771663B (zh) | E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法 | |
| KR20240110660A (ko) | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 | |
| TW201615211A (zh) | 新穎多醣體及其用途 | |
| KR101266552B1 (ko) | 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합 | |
| AU2021342797B2 (en) | Multivalent vaccine compositions and uses thereof | |
| Altman et al. | Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1, 6-glucan chain | |
| US20220323576A1 (en) | Production of E. coli O18 Bioconjugates | |
| AU2005243548A1 (en) | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates | |
| JPWO2021255684A5 (de) | ||
| JP2004506086A (ja) | インフルエンザ菌感染症の予防用ワクチンとしてのインフルエンザ菌リポ多糖内部コアオリゴ糖エピトープ | |
| RU2818894C1 (ru) | Свободные от примеси с-полисахарида капсульные полисахариды streptococcus pneumoniae с остатком 2,5-ангидроманнозы на восстанавливающем конце | |
| TW202434282A (zh) | 多價疫苗組合物及其用途 | |
| EA046636B1 (ru) | Способы получения биоконъюгатов полисахаридных о-антигенов e. coli, их композиции и способы их применения | |
| JP2023530154A (ja) | 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート | |
| EA046206B1 (ru) | Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения |